Bellerophon Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bellerophon Therapeutics Inc.
Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.
MATTERHORN’s failure did not surprise analysts, but it’s likely the end of the road for roxadustat in the US market. The focus instead has shifted to FibroGen’s IPF asset pamrevlumab.
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
In Scrip’s new column tracking clinical trial developments, NewAmsterdam, CatalYm, Verve, Bellerophon and Almirall announced new trials or changes to existing ones, while CROs Parexel and PPD announced new programs and CTI appointed a new exec.
- Drug Delivery
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.